source
- FDA Announces First Participant Selected for TEMPO for Digital Health Devices PilotThe U.S. Food and Drug Administration today announced the first manufacturer selected for the Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot.fda press · 8d ago↗ source
- Safety and Toxicity Management in Metastatic Castration-Resistant Prostate CancerDr. Johann De Bono and Dr. Pedro Barata discuss practical approaches to monitoring and managing toxicities associated with radiopharmaceutical therapies in metastatic castration-resistant prostate…onclive · 2mo ago↗ source
- Combination and Sequencing Strategies in Metastatic Castration-Resistant Prostate CancerDr. Pedro Barata and Dr. Johann De Bono discuss ongoing questions surrounding combination approaches and optimal sequencing strategies for radiopharmaceutical therapies in metastatic castration-res…